Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associa… Read more
Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Net Assets
Latest net assets as of September 2025: $119.25 Million USD
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has net assets worth $119.25 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($128.40 Million) and total liabilities ($9.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $119.25 Million |
| % of Total Assets | 92.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Sagimet Biosciences Inc. Series A Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sagimet Biosciences Inc. Series A Common Stock (2019–2024)
The table below shows the annual net assets of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $155.81 Million | +71.09% |
| 2023-12-31 | $91.06 Million | +148.71% |
| 2022-12-31 | $-186.95 Million | -18.13% |
| 2021-12-31 | $-158.26 Million | -16.44% |
| 2020-12-31 | $-135.91 Million | -8.45% |
| 2019-12-31 | $-125.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sagimet Biosciences Inc. Series A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13975400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $230.00K | 0.15% |
| Other Components | $450.88 Million | 289.39% |
| Total Equity | $155.81 Million | 100.00% |
Sagimet Biosciences Inc. Series A Common Stock Competitors by Market Cap
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Al Aqar Healthcare Reit
KLSE:5116
|
$150.46 Million |
|
Magnetic Resources NL
AU:MAU
|
$150.55 Million |
|
Greene County Bancorp Inc
NASDAQ:GCBC
|
$150.59 Million |
|
Gesher Acquisition Corp. II
NASDAQ:GSHR
|
$150.61 Million |
|
Shenzhen Auto Electric Power Plant Co Ltd
SHE:002227
|
$150.39 Million |
|
Izmir Firca Sanayi ve Ticaret
IS:IZFAS
|
$150.37 Million |
|
Gencor Industries Inc
NYSE MKT:GENC
|
$150.36 Million |
|
Is Finansal Kiralama AS
IS:ISFIN
|
$150.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sagimet Biosciences Inc. Series A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 91,065,000 to 155,805,000, a change of 64,740,000 (71.1%).
- Net loss of 45,567,000 reduced equity.
- New share issuances of 105,750,000 increased equity.
- Other comprehensive income increased equity by 200,000.
- Other factors increased equity by 4,357,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.57 Million | -29.25% |
| Share Issuances | $105.75 Million | +67.87% |
| Other Comprehensive Income | $200.00K | +0.13% |
| Other Changes | $4.36 Million | +2.8% |
| Total Change | $- | 71.09% |
Book Value vs Market Value Analysis
This analysis compares Sagimet Biosciences Inc. Series A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-5.65 | $5.19 | x |
| 2020-12-31 | $-6.13 | $5.19 | x |
| 2021-12-31 | $-7.14 | $5.19 | x |
| 2022-12-31 | $-8.43 | $5.19 | x |
| 2023-12-31 | $5.01 | $5.19 | x |
| 2024-12-31 | $4.97 | $5.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sagimet Biosciences Inc. Series A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-29.25%) is below the historical average (-9.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.73 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $2.22 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.62 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.80 Million |
| 2023 | -30.61% | -1393.80% | 0.02x | 1.06x | $-36.98 Million |
| 2024 | -29.25% | 0.00% | 0.00x | 1.03x | $-61.15 Million |
Industry Comparison
This section compares Sagimet Biosciences Inc. Series A Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sagimet Biosciences Inc. Series A Common Stock (SGMT) | $119.25 Million | 0.00% | 0.08x | $150.46 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |